Related Experiment Video
Updated: Jul 14, 2025
07:48
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
11.4K
Targeting sphingosine kinase 1 in p53KO thymic lymphoma
Fabiola N Velazquez1,2, Jeffrey L Stith1,2, Leiqing Zhang1,2
1Department of Medicine, Stony Brook University, Stony Brook, New York, USA.
Summary
Targeting sphingosine kinase 1 (SK1) inhibits lymphoma growth in p53-deficient mice. This approach increases cell death and sphingosine levels, offering a new therapeutic strategy for tumors lacking p53 function.
Area of Science:
- Oncology
- Biochemistry
- Molecular Biology
Background:
- Sphingosine kinase 1 (SK1) is upregulated in various cancers, including lymphoma.
- Tumor protein P53 (p53) mutations or deletion are associated with poor lymphoma prognosis.
- SK1 is a potential therapeutic target, but its role in p53-deleted cancers is unexplored.
Purpose of the Study:
- To evaluate the therapeutic potential of targeting SK1 in lymphoma lacking p53 function.
- To investigate the impact of SK1 inhibition on tumor growth and cell death in p53-deficient lymphoma models.
Main Methods:
- Utilized genetic (inducible deletion of Sphk1) and pharmacological inhibition of SK1 in Trp53KO mice.
- Assessed tumor growth, cell death, and sphingolipid levels in established p53KO thymic lymphoma models.
Main Results:
- Targeting SK1 significantly decreased tumor growth in established p53KO thymic lymphoma.
- SK1 inhibition led to increased tumor cell death.
- Pharmacological or genetic inhibition of SK1 resulted in selective sphingosine accumulation.
Conclusions:
- SK1 plays a critical role in the growth and maintenance of lymphoma in the absence of p53.
- SK1 is a promising therapeutic target for treating lymphomas with p53 deletion or mutations.
- Targeting SK1 represents a potential strategy for improving outcomes in p53-deficient tumors.
Related Concept Videos
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K